Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
BoFA Says Novo Nordisk May Miss Q1 Expectations as Wegovy, Ozempic Sales Lag
GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales ...
Novo Nordisk inks licensing pact with Lexicon for obesity candidate
Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...
Fierce Biotech12h
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...